Clinical trials
Hepatocellular Carcinoma (HCC) clinical trials
Below are recruiting hepatocellular carcinoma (hcc) clinical trials, each written for real people, not researchers. We’re tracking 484 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05185739RecruitingPhase 2
Pembrolizumab and lenvatinib before liver surgery for resectable cancer
This trial tests whether giving pembrolizumab (an immune therapy) and lenvatinib (a targeted pill) before planned liver surgery can improve outcomes for people with certain types of operable hepatocellular carcinoma (HCC). It’s meant for tumors that can be removed with curative intent, but still carry a risk of coming back.
BirminghamAges 18 years+ - NCT05203120Recruiting
Proton beam radiation for liver cancer that can’t be removed
This study tests proton beam radiation for people with liver cancer that is still inside the liver but cannot be treated with surgery or a small-needle procedure. Proton beams aim to better target the tumor while reducing radiation to nearby organs.
Herlev, Capital RegionAges 18 years+ - NCT05257590RecruitingPhase 2
CVM-1118 plus nivolumab for advanced liver cancer
This Phase 2 trial tests whether CVM-1118 given with nivolumab can help people with advanced, unresectable hepatocellular carcinoma (a type of liver cancer) that can’t be cured with surgery. It’s for patients whose cancer has worsened after earlier cancer medicines or treatments.
Kaohsiung CityAges 18 years+ - NCT05304481RecruitingPhase 2
Activated immune cells after liver tumor removal for HCC
This Phase 2 study tests an immune-cell treatment (activated T lymphocytes) given after your liver cancer tumor has been fully removed. It aims to improve safety and reduce the chance of the cancer coming back in people with early-stage hepatocellular carcinoma.
Hualien City, TaiwanAges 20 years+ - NCT05317819RecruitingPhase 3
Test ADI-PEG 20 versus placebo for advanced liver cancer
This study tests whether ADI-PEG 20 helps people with advanced, unresectable hepatocellular carcinoma (liver cancer) who have high arginine levels. Participants get ADI-PEG 20 or a placebo to see which works better and improves outcomes.
ChanghuaAges 18–99 - NCT05366829RecruitingPhase 2
Tislelizumab after liver tumor radiation to reduce cancer return
This Phase 2 trial tests tislelizumab (an immunotherapy medicine) given after liver-directed radiation to help prevent hepatocellular carcinoma (liver cancer) from coming back or spreading. It may help by boosting the immune system to better control remaining cancer.
New Brunswick, New JerseyAges 18 years+ - NCT05408221RecruitingPhase 2/Phase 3
Liver cancer trial testing Rulonilimab plus Lenvatinib
This Phase 2/3 study tests whether combining rulonilimab with lenvatinib can control unresectable advanced liver cancer (HCC) that cannot be removed by surgery or treated locally. You may be considered if you have not had prior whole-body (systemic) cancer treatments and your organs and blood counts are strong enough.
Beijing, Beijing MunicipalityAges 18–75 - NCT05440708RecruitingPhase 1/Phase 2
Study drug for advanced liver cancer that cannot be removed
This trial tests TTI-101, by itself and with other cancer medicines, for liver cancer that is advanced and cannot be removed by surgery. It aims to see whether the treatment can slow the cancer down and improve outcomes.
Birmingham, AlabamaAges 18 years+ - NCT05444478Recruiting
Microwave ablation plus lenvatinib for recurrent liver cancer
This trial tests whether combining heat treatment to kill liver tumors (microwave ablation) with the medicine lenvatinib can better control recurrent hepatocellular carcinoma (HCC). It may help shrink tumors or slow growth for people whose cancer has come back but who have limited tumor burden.
Changsha, HunanAges 18–75 - NCT05516628RecruitingPhase 2
Adjuvant atezolizumab plus bevacizumab after liver cancer surgery
This trial studies whether adding atezolizumab and bevacizumab after complete liver cancer surgery can lower the chance the cancer comes back. It also uses “multi-omics” tests (special lab tests on your tissue/blood) to help predict who is more likely to respond or resist treatment.
SingaporeAges 21–90 - NCT05528952RecruitingPhase 2
Vaccine plus immunotherapy for unresectable liver cancer
This Phase 2 trial studies whether adding a cancer vaccine (to help the immune system recognize your tumor) to two medicines—atezolizumab and bevacizumab—can better control unresectable or advanced liver cancer. It’s for people who haven’t had prior whole-body (systemic) cancer treatment.
BesançonAges 18 years+ - NCT05613478RecruitingPhase 3
Immunotherapy plus targeted medicine with TACE around liver surgery
This Phase 3 trial tests whether combining camrelizumab and apatinib with TACE before/around liver cancer surgery can improve outcomes for people with certain stages of hepatocellular carcinoma (HCC). It may help by strengthening the immune attack on cancer and by blocking blood supply to tumors.
Nanjing, JiangsuAges 18 years+ - NCT05669339RecruitingPhase 2
AI-guided dosing study for advanced liver cancer patients
This Phase 2 study tests whether an artificial intelligence tool can help doctors choose the right dose for treating advanced hepatocellular carcinoma (HCC), a type of liver cancer. It aims to improve safety and effectiveness by matching treatment to you using your liver function, lab results, and treatment course.
Gainesville, FloridaAges 18–99 - NCT05687747RecruitingPhase 1
68Ga-FAPI PET/MRI scan for liver cancer diagnosis
This trial studies how well a special imaging test (68Ga-FAPI PET/MRI) can detect and evaluate hepatocellular carcinoma (HCC), a type of liver cancer. It may help doctors confirm diagnosis and plan next steps by seeing how the cancer takes up the tracer.
SingaporeAges 21–99 - NCT05713994Recruiting
Liver cancer treatments together for unresectable liver tumors
This trial tests a combined treatment plan—chemo delivered to the liver, targeted therapy, anti-VEGF therapy, and immunotherapy—to control unresectable hepatocellular carcinoma (HCC). It may help shrink tumors or slow progression when surgery isn’t possible.
Quanzhou, FujianAges 18 years+ - NCT05717738Recruiting
Immunotherapy plus targeted drugs after TACE for liver cancer
This trial tests a combination of blood-vessel–targeting medicine and immunotherapy after a liver-directed treatment called TACE for advanced hepatocellular carcinoma (HCC). It aims to control tumor growth when surgery or ablation isn’t suitable, and to see if this “conversion therapy” helps patients do better than standard pathways.
Quanzhou, FujianAges 18 years+ - NCT05809869RecruitingPhase 2
Immunotherapy plus liver radiation for metastatic liver cancer
This trial tests whether combining an immunotherapy drug with a special type of liver radiation (yttrium-90) can control metastatic hepatocellular carcinoma (liver cancer that has spread). It may help by boosting your immune system and shrinking liver tumors at the same time.
Hong KongAges 18 years+ - NCT05810402Recruiting
Testing immunotherapy for advanced liver cancer using blood tests
This study looks at how well immune-checkpoint therapy (a PD-1 or PD-L1 immunotherapy) works for advanced liver cancer, using “liquid biopsy” blood testing to guide or monitor care. It may help your team better track your cancer and response without needing repeated tissue biopsies.
MontpellierAges 18 years+ - NCT05842174RecruitingPhase 1/Phase 2
Checking a new treatment approach for liver cancer needing TACE
This early-stage trial studies a new strategy for hepatocellular carcinoma (a type of liver cancer) in people who are planned to receive TACE, a procedure that delivers treatment through the liver’s blood supply. It aims to test whether targeting a specific cell survival process can improve how well the treatment works and is tolerated.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05844046RecruitingPhase 2
Triple drug treatment for advanced liver cancer that can’t be removed
This Phase 2 trial tests three medicines together (durvalumab, tremelimumab, and bevacizumab) to treat non-surgical (non-resectable) liver cancer. It may help shrink tumors and slow disease progression by boosting the immune system and blocking tumor blood supply.
MunichAges 18 years+ - NCT05871892Recruiting
PET/CT or PET/MRI scans for suspected or diagnosed liver cancer
This study looks at how well special imaging scans (PET/CT or PET/MRI) work in adults with suspected or diagnosed liver cancer. It may help doctors better see the cancer and plan next steps.
AarhusAges 18–100 - NCT05901519RecruitingPhase 2
Prednisone to protect the liver during focused radiation for liver cancer
This trial tests whether prednisone (an anti-inflammatory steroid) can help protect the liver in people with hepatocellular carcinoma who are getting stereotactic body radiation therapy. It may reduce liver stress from radiation and help you tolerate treatment safely.
Ann Arbor, MichiganAges 18 years+ - NCT05926726Recruiting
GPC3-targeted CAR-T for advanced liver cancer
This trial tests a custom immune-cell treatment (CAR-T) that targets a marker called GPC3 in people with advanced hepatocellular carcinoma (a type of liver cancer). It’s for cases where standard treatments have not worked well, and the goal is to shrink tumors and improve outcomes.
ShanghaiAges 18–75 - NCT05954897RecruitingPhase 2
Lenvatinib plus tislelizumab with HAIC for advanced liver cancer
This Phase 2 study tests whether combining three treatments—lenvatinib, tislelizumab, and a liver-directed chemotherapy approach (HAIC)—can shrink advanced hepatocellular carcinoma. It may help people whose cancer is stage C and hasn’t been treated before.
Guangzhou, GuangdongAges 18 years+
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma (hcc)?
- Yes. Clin2 currently lists 484 recruiting hepatocellular carcinoma (hcc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma (hcc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma (hcc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.